World Journal of Surgical Oncology最新文献

{"title":"Long-term outcomes of proximal gastrectomy versus total gastrectomy for clinically advanced upper-third gastric cancer: an inverse probability weighting analysis.","authors":"Hayato Shimoyama, Shusuke Haruta, Kentoku Fujisawa, Yusuke Ogawa, Yu Ohkura, Masaki Ueno, Harushi Udagawa","doi":"10.1186/s12957-025-03946-4","DOIUrl":"10.1186/s12957-025-03946-4","url":null,"abstract":"<p><strong>Background: </strong>Proximal gastrectomy is commonly performed for early upper-third gastric cancers; however, in no studies have the long-term outcomes of total and proximal gastrectomy been compared for clinically advanced upper-third gastric cancer. We assessed the outcomes of both techniques in this context.</p><p><strong>Methods: </strong>Patients who underwent proximal or total gastrectomy for clinically advanced upper-third gastric cancer (tumor diameter ≤ 50 mm) between June 1994 and July 2021 at Toranomon Hospital, Japan, were included. We compared overall and relapse-free survival between the total gastrectomy (TG) and proximal gastrectomy (PG) groups using inverse probability of treatment weighting, analyzed whether the surgical technique was an independent risk factor for death or recurrence using a Cox proportional hazards model, and evaluated the therapeutic effect using the therapeutic value index for the lymph nodes dissected in TG but undissected in PG.</p><p><strong>Results: </strong>We investigated 45 and 35 patients in the TG and PG groups, respectively. The 5-year overall and relapse-free survival of the TG and PG groups were 59.4% vs. 61.2%, P = 0.921; and 56.5% vs. 57.1%, P = 0.984; respectively. Surgical technique was not an independent risk factor for death or recurrence. The therapeutic value indexes of the relevant lymph nodes (#3b/4d/5/6/12a) were all zero.</p><p><strong>Conclusions: </strong>Proximal gastrectomy for relatively small clinically advanced upper-third gastric cancer may be acceptable because its 5-year overall and relapse-free survival do not differ significantly from that of total gastrectomy, it is not an independent risk factor for death or recurrence, and no therapeutic effect for the omitted lymph nodes was revealed.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"288"},"PeriodicalIF":2.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytoreductive surgery with multimodal therapies in advanced or metastatic ovarian, colorectal, and gastric cancers: a systematic review and meta-analysis of randomized trials.","authors":"Xiaojun Yuan, Huazheng Liang, Xinxin Fu, Shirui Yang, Chenyu Xiang, Zisheng Chen","doi":"10.1186/s12957-025-03908-w","DOIUrl":"10.1186/s12957-025-03908-w","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence supports cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer, yet its efficacy in other malignancies, such as gastric and colorectal cancers, remains uncertain. This meta-analysis evaluates survival outcomes in patients with advanced or metastatic ovarian, colorectal, and gastric cancers treated with CRS and multimodal therapies (e.g., HIPEC, extensive intraoperative peritoneal lavage (EIPL), systemic chemotherapy, immunotherapy, targeted therapy) versus CRS alone or with control-based regimens, focusing on the applicability of these treatments to these specific cancers.</p><p><strong>Methods: </strong>We systematically searched PubMed, EMBASE, Web of Science, the Cochrane Library, and the abstracts of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) congresses up to April 21, 2025, for randomized trials published in English. The primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes included mortality, adverse events, and 3- and 5-year OS rates. Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled using fixed- or random-effects models, depending on heterogeneity (I²).</p><p><strong>Findings: </strong>From 16,064 records, 13 studies (n = 3,925 patients, control group = 1,894, experimental group = 2,031) met inclusion criteria. The experimental group significantly improved OS (HR: 0.86, 95% CI: 0.77 - 0.95, P = 0.003, I² = 22%, P = 0.26) and PFS (HR: 0.67, 95% CI: 0.50 - 0.90, P = 0.009, I² = 83%, P < 0.001) compared to the control group. Subgroup analyses highlighted heterogeneity in PFS benefits, with recent trials (published in or after 2023) showing more potent effects (HR: 0.53, 95% CI: 0.44 - 0.64, P < 0.001). Mortality reduction favored the experimental group (risk ratio (RR): 0.86, 95% CI: 0.75 - 0.99, P = 0.03, I² = 26%, P = 0.24), though clinical relevance requires cautious interpretation. The experimental group significantly increased grade 3 or worse adverse events (RR: 1.31, 95% CI: 1.16 - 1.48, P < 0.001, I² = 31%, P = 0.04), with significant effects driven by digestive system (RR: 1.43, 95% CI: 1.06 - 1.93) and circulatory system (RR: 1.58, 95% CI: 1.07 - 2.32) events.</p><p><strong>Interpretation: </strong>CRS combined with multimodal therapies, confers significant survival benefits in advanced ovarian, colorectal, and gastric cancers despite elevated complication risks. These findings support the tailored integration of multimodal strategies in selected patients, highlighting the need for robust randomized trials to validate long-term efficacy and safety.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"286"},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors and predictive thresholds for postoperative pleural effusion in children with neuroblastoma: a retrospective cohort study.","authors":"Jing Hu, Ping Chu, Jun Feng, Xinran He, Lijing Li, Yi Ren, Zhe Su, Wei Yang, Jianmin Zhang, Fang Wang","doi":"10.1186/s12957-025-03936-6","DOIUrl":"10.1186/s12957-025-03936-6","url":null,"abstract":"<p><strong>Background: </strong>Postoperative pleural effusion is a common complication after neuroblastoma resection in children. Evidence-based risk stratification remains limited. This study aimed to identify independent risk factors for postoperative pleural effusion and to establish clinically actionable thresholds for perioperative risk mitigation.</p><p><strong>Methods: </strong>We analyzed 165 pediatric patients who underwent abdominal neuroblastoma resection between 2018 and 2020. Data regarding 82 variables across five dimensions were retrospectively collected from the preoperative period to 3 years postoperatively. The primary endpoint was postoperative pleural effusion requiring intervention. Continuous variables were dichotomized using cutoff values derived from receiver operating characteristic (ROC) curves to maximize outcome discrimination. Multivariable logistic regression was utilized to identify independent risk factors for postoperative pleural effusion; adjusted odds ratios (aORs) reflected the magnitude of association.</p><p><strong>Results: </strong>Postoperative pleural effusion requiring intervention occurred in 21.82% of neuroblastoma patients. ROC curve analysis identified critical thresholds for risk factors: body mass index (BMI) Z-score = -0.96 SD, preoperative hemoglobin = 99.00 g/L, operative time = 4.33 h, albumin on postoperative day 1 = 32.30 g/L, and C-reactive protein on postoperative day 1 = 20.00 mg/L. Multivariable logistic regression analysis revealed that a slightly below-normal BMI Z-score (aOR = 10.20; 95% confidence interval [CI], 1.11-92.20; P = 0.039), adrenal origin of the tumor (aOR = 16.20; 95% CI, 1.21-215.60; P = 0.035), lower preoperative hemoglobin (aOR = 9.88; 95% CI, 1.69-57.76; P = 0.011), prolonged operative time (aOR = 180.20; 95% CI, 7.43-4373.99; P = 0.001), lower albumin on postoperative day 1 (aOR = 17.13; 95% CI, 3.26-90.14; P < 0.001), and elevated C-reactive protein on postoperative day 1 (aOR = 6.07; 95% CI, 1.21-30.40; P = 0.028) were independently associated with an increased risk of postoperative pleural effusion.</p><p><strong>Conclusions: </strong>In pediatric patients undergoing neuroblastoma resection, prolonged operative time may indicate increased systemic inflammation. Perioperative inflammation modulation might represent a potential target for risk reduction, while maintaining adequate albumin levels and optimizing preoperative nutrition could be considered as supportive strategies. These findings are preliminary and require confirmation in larger prospective studies.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry (ChiCTR2500096561; 01/26/2025).</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"282"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis.","authors":"Jichao Zhu, Jiliang Zhang, Chao Gu","doi":"10.1186/s12957-025-03949-1","DOIUrl":"10.1186/s12957-025-03949-1","url":null,"abstract":"<p><strong>Background: </strong>The effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.</p><p><strong>Methods: </strong>We retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.</p><p><strong>Results: </strong>Six studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; p = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; p < 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52-3.14; p = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; p = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; p = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; p = 0.620) in CRC.</p><p><strong>Conclusions: </strong>Elevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"283"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performing sentinel lymph node biopsy without a hand-held gamma probe - overcoming hurdles through team work: an analysis of our learning curve over five years.","authors":"Ranganath Ratnagiri, Madhur Kumar Srivastava, Megha S Uppin, Monalisa Hui, C Rachana, Monica I Mallik, Rajashekhar Shantappa","doi":"10.1186/s12957-025-03938-4","DOIUrl":"10.1186/s12957-025-03938-4","url":null,"abstract":"<p><strong>Background: </strong>Sentinel lymph node biopsy is the standard of care in the management of node negative axilla in breast cancer and in node negative melanomas and penile cancers. The wide spread adoption of this procedure is however, hampered by the availability of the hand-held gamma probe.</p><p><strong>Aim: </strong>To demonstrate the safety and feasibility of sentinel node biopsy using methylene blue and SPECT CT lymphoscintigraphy.</p><p><strong>Patients and methods: </strong>A retrospective review of the case records of all patients of breast cancer, penile cancer and melanomas who underwent surgery at our Institute between December 2019 and November 2024 was analysed. Demographic data, operative data, pathological reports and follow up data were analysed.</p><p><strong>Results: </strong>Out of a total of 628 patients operated for the above cancers, 70 patients underwent a sentinel lymph node biopsy along with surgery for the primary. Localization was possible in all the patients (100%). The time taken to localize the node decreased from 33 min to 16 min over the course of the learning curve (percentage change of -50%). The median number of nodes isolated increased by 200% and the seroma in the nodal basin decreased by 26%. Recurrences in the nodal basin were commonest in penile cancer (16.6%), while those in the axilla (6.5%) could be salvaged surgically.</p><p><strong>Conclusion: </strong>Sentinel node biopsy can be safely performed even without a hand-held gamma probe, provided strict inclusion criteria, a double dye technique and a dedicated follow up regimen are adhered to.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"285"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes and prognostic impact of adjuvant chemotherapy in stage IB lung adenocarcinoma with cribriform component.","authors":"Rongyang Li, Yu Zhang, Jianhao Qiu, Mingyang Zang, Zhenguo Sun","doi":"10.1186/s12957-025-03947-3","DOIUrl":"10.1186/s12957-025-03947-3","url":null,"abstract":"<p><strong>Background: </strong>Cribriform morphology is a distinct high-grade pattern associated with aggressive tumor biology and poor survival outcomes in lung adenocarcinoma (LUAD). The potential survival benefits of adjuvant chemotherapy (ACT) for stage IB LUAD containing cribriform components remain undefined. This study aims to investigate the prognostic significance of ACT in patients with stage IB LUAD containing cribriform components.</p><p><strong>Methods: </strong>This retrospective study enrolled 235 surgically resected LUAD patients with pathologically confirmed stage IB disease from Qilu Hospital of Shandong University. To mitigate selection bias, propensity score matching (PSM) was implemented with 1:1 nearest-neighbor matching. Survival outcomes were compared using Kaplan-Meier methodology with log-rank testing for intergroup comparisons. Univariate and Multivariate Cox proportional hazards models were constructed to identify independent prognostic factors.</p><p><strong>Results: </strong>Patients were stratified into cribriform-positive and cribriform-negative cohorts based on histologically confirmed cribriform component status, resulting in 67 patients with cribriform components and 168 patients without this histopathological feature. After PSM, 59 pairs of patients were finally included for analysis. The results showed that both the 5-year overall survival (OS) rates (63.5% vs. 84.5%, P = 0.013) and 5-year recurrence-free survival (RFS) rates (58.7% vs. 77.7%, P = 0.033) for cribriform-positive patients were lower than those for cribriform-negative patients. In addition, we further explored whether patients with cribriform components could derive a survival benefit from postoperative ACT. The results indicated that patients receiving ACT demonstrated a significant improvement in 5-year rates of RFS compared to observation-only management (70.2% vs. 38.6%, P = 0.0096). Univariate and multivariate Cox proportional hazards regression analyses identified the resection range (HR = 0.197; 95% CI: 0.061-0.632; P = 0.006), STAS (HR = 2.653; 95% CI: 1.131-6.221; P = 0.025), and ACT (HR = 0.334; 95% CI: 0.151-0.742; P = 0.007) as independent prognostic factors for RFS.</p><p><strong>Conclusion: </strong>The presence of cribriform components in stage IB LUAD was associated with diminished survival prognosis. Patients with stage IB LUAD containing cribriform components could derive survival benefit from postoperative ACT.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"284"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome as a prognostic factor in advanced pancreatic cancer: a predictive model and chemotherapy evaluation.","authors":"Jingchang Zhang, Jianbiao Li, Huiting Deng, Yongfu Zhao, Ye Zhang","doi":"10.1186/s12957-025-03940-w","DOIUrl":"10.1186/s12957-025-03940-w","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify independent prognostic factors for advanced unresectable pancreatic ductal adenocarcinoma (PDAC) and construct a nomogram-based prediction model. The efficacy of different chemotherapy regimens was evaluated based on metabolic risk levels.</p><p><strong>Methods: </strong>Clinical data from 276 patients with unresectable PDAC treated between 2020 and 2022 were retrospectively analyzed. Cox proportional hazards regression identified prognostic factors, and survival analysis was performed using Kaplan-Meier methods. A nomogram was developed, and ROC analysis assessed its predictive performance. Two-way ANOVA evaluated chemotherapy efficacy, and TCGA transcriptomic data explored metabolic correlations.</p><p><strong>Results: </strong>Metabolic syndrome (MetS) and distant metastasis were independent prognostic factors. Patients with MetS had significantly shorter survival. The nomogram showed good discrimination (AUC: 0.815 training, 0.793 validation). Patients without MetS had better outcomes with FOLFIRINOX or GS regimens. Transcriptomic analysis revealed metabolic pathways linked to PDAC progression.</p><p><strong>Conclusions: </strong>MetS and distant metastasis significantly impact PDAC prognosis. Patients without MetS benefit more from specific chemotherapy regimens. Our predictive model may aid personalized treatment strategies.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"281"},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144650648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the triglyceride-glucose index (TyG Index) and risk of colorectal cancer: a systematic review and meta-analysis.","authors":"Hala Fathi EmamElkhir Omer, Mohamed Alghazali, Mohamed Y Ibrahim, Nadeen Mohamed Yousif Abdalla, Ashraf Hassan Mohamed Hassan, Eram Asim Seidahmed Yousif, Aseel E B Abdhameed, Yaser Waheeb Slaiman Naser, Nawras Mustafa Elashai Hamad, Malaz A I Abdalla, Mohamed Osman Mohamed Idres, Ali Abdelhaleem Omar Ahmed, Yasir Ahmed Mohammed Elhadi, Sagad O O Mohamed","doi":"10.1186/s12957-025-03930-y","DOIUrl":"10.1186/s12957-025-03930-y","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is one of the most common malignancies worldwide, with increasing evidence linking metabolic dysregulation, such as insulin resistance and chronic inflammation, to its development and progression. A potential useful predictor of CRC risk is the triglyceride-glucose (TyG) index, a marker for insulin resistance that is determined using fasting triglyceride and glucose levels. The purpose of this systematic review was to assess the relationship between the TyG index and CRC and ascertain whether the TyG index is associated with the development and outcomes of CRC.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was reported in accordance with the PRISMA guidelines. Comprehensive searches of PubMed, Web of Science, Scopus, and World Health Organization Virtual Health Library were conducted in 24th March 2025 to find studies assessing the relationship between the TyG index and CRC. Results of association between TyG index and CRC were summarized and a meta-analysis was done to calculate pooled hazard ratio (HR) with 95% confidence interval (CI).</p><p><strong>Results: </strong>A total of eight studies were included in the systematic review, of which five met the criteria for inclusion in the quantitative synthesis. The pooled analysis showed that the hazard of developing CRC was significantly greater for those with a higher TyG index (HR = 1.18; 95% CI: 1.12-1.25; P <.001). In addition, meta-analysis indicated that hazard of developing CRC significantly increased for each one-unit increase in the TyG index (HR = 1.28, 95% CI: 1.18 to 1.39, P <.001).</p><p><strong>Conclusion: </strong>Higher TyG index level is substantially linked to an elevated hazard of developing CRC. Therefore, the TyG index can be a useful tool for CRC risk identification. Standardizing cut-off values and researching clinical applicability in various populations should be the main goals of future research. Due to the limitations posed by the small number of studies, further prospective studies are needed to generate more robust and generalizable evidence.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"280"},"PeriodicalIF":2.5,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impairment of neck and shoulder function after neck dissection: a comparative study of goniometry, EMG and paper pencil tool in a randomized controlled trial of level IIb preserving verses conventional neck dissection.","authors":"Senniappan Karthikeyan, Deepika Joshi, Abhishek Pathak, Manoj Pandey","doi":"10.1186/s12957-025-03931-x","DOIUrl":"10.1186/s12957-025-03931-x","url":null,"abstract":"<p><strong>Background: </strong>Surgical management of oral cancer poses significant challenges due to the proximity of critical nerves, like spinal accessory, which increases the risk of inadvertent damage or neuropraxia during surgery.</p><p><strong>Methods: </strong>A randomized controlled trial enrolled 32 patients with histologically confirmed oral cavity carcinoma and clinically and radiologically negative cervical neck nodes. Patients were assigned to either level IIb-preserving or conventional selective neck dissection. Shoulder function was evaluated using goniometry, electromyography (EMG), and the Neck Dissection Impairment Index (NDII). Outcomes from these three assessment methods were compared.</p><p><strong>Results: </strong>Both groups exhibited impaired spinal accessory nerve function. In the IIb-preserving group, EMG detected impairment in 50% of patients, compared to 95% in the control group. Statistically significant differences were observed between groups across all three assessment methods. However, EMG and goniometry indicated functional recovery at 6 and 12 months, whereas NDII scores remained significantly different at 12 months, despite full nerve recovery observed on EMG and goniometry.</p><p><strong>Conclusions: </strong>The study demonstrates agreement between shoulder function measurements (goniometry and EMG) but discordance with NDII. This discrepancy may arise from the distinct constructs used by NDII to assess neck dissection impairment, highlighting potential limitations in its sensitivity to functional recovery.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"279"},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IGF2BP1 promotes the progression of head and neck squamous cell carcinoma by activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition.","authors":"Ruibing Liu, Guohua Hu, Yanshi Li, Tao Lu, Min Pan, Mengna Wang, Zhaobo Cheng, Lin Chen","doi":"10.1186/s12957-025-03929-5","DOIUrl":"10.1186/s12957-025-03929-5","url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) ranks as the sixth most prevalent cancer globally, with lymph node metastasis being a primary contributor to poor patient prognosis. Elucidating the molecular mechanisms driving HNSCC lymphatic metastasis is imperative for developing targeted therapeutic strategies and improving patient survival.</p><p><strong>Methods: </strong>The expression of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in HNSCC samples was evaluated using The Cancer Genome Atlas (TCGA), RT-qPCR, Western blotting, and immunohistochemical analysis. The impact of IGF2BP1 on HNSCC cell proliferation was assessed through CCK-8 assay, plate cloning, and EdU assays. Cell motility was examined by Transwell migration and invasion assays. A tumor lymph node metastasis model in nude mice was established to evaluate the role of IGF2BP1 in lymphatic metastasis. Additionally, the regulatory effects of IGF2BP1 on the epithelial-mesenchymal transition (EMT) and the PI3K/AKT/mTOR signaling pathways were investigated using immunofluorescence and Western blotting.</p><p><strong>Results: </strong>IGF2BP1 expression was significantly elevated in HNSCC tissues compared to adjacent normal tissues and was strongly associated with lymph node metastasis and poor prognosis. Knockdown of IGF2BP1 suppressed the proliferation, migration, and invasion of HNSCC cells. Furthermore, IGF2BP1 knockdown inhibited tumor growth and lymphatic metastasis in vivo. Mechanistically, IGF2BP1 was found to promote the EMT process by activating the PI3K/AKT/mTOR pathway, thereby enhancing the migratory and invasive capabilities of HNSCC cells.</p><p><strong>Conclusions: </strong>Our findings demonstrate that IGF2BP1 plays a critical role in promoting HNSCC growth and metastasis, highlighting its potential as a therapeutic target.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"277"},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}